24 May

What do recent SPC decisions mean for life sciences companies?

SPCs are crucial to the IP strategies of life sciences innovators, extending exclusivity when profitability is typically at its highest point. With a number of ECJ decisions addressing tricky disputes in the past 12 months, it is important for biopharma IP professionals to understand recent changes in the obstacles and opportunities involving SPCs

Adam Houldsworth

Life sciences reporter


[email protected]